Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Operating Income (2019 - 2025)

Historic Operating Income for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $65.5 million.

  • Harmony Biosciences Holdings' Operating Income rose 612.06% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 2871.96%. This contributed to the annual value of $190.8 million for FY2024, which is 62.7% down from last year.
  • Harmony Biosciences Holdings' Operating Income amounted to $65.5 million in Q3 2025, which was up 612.06% from $48.2 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Operating Income high stood at $65.5 million for Q3 2025, and its period low was $11.9 million during Q3 2022.
  • Its 5-year average for Operating Income is $40.0 million, with a median of $40.4 million in 2023.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Operating Income surged by 44204.69% in 2023 and then crashed by 5446.68% in 2024.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Operating Income stood at $28.6 million in 2021, then surged by 66.3% to $47.6 million in 2022, then dropped by 15.58% to $40.2 million in 2023, then surged by 38.64% to $55.7 million in 2024, then rose by 17.51% to $65.5 million in 2025.
  • Its Operating Income was $65.5 million in Q3 2025, compared to $48.2 million in Q2 2025 and $56.2 million in Q1 2025.